How to prescribe Triumeq?
Once-daily TRIUMEQ makes dosing and administration simple for your patients
TRIUMEQ (dolutegravir/abacavir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. 1
Dosing recommendation 1
Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.  Find out more on HLA-B*5701 screening here.
Dolutegravir should not be prescribed to women seeking to become pregnant. Women who can become pregnant should use effective contraception while taking dolutegravir 1
Triumeq should not be co-administered with polyvalent cation-containing antacids, supplements or multivitamins containing calcium, iron or magnesium. Triumeq is recommended to be administered 2 hours before or 6 hours after these medicinal products.
Dolutegravir increased metformin concentrations. A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin, to maintain glycaemic control. Metformin is eliminated renally and therefore it is of importance to monitor renal function when co-treated with dolutegravir.
For further information, please see Triumeq preparatomtale
*TRIUMEQ is a fixed-dose pill and should not be prescribed for patients requiring dose adjustments. Separate preparations of dolutegravir, abacavir, and lamivudine are available in cases where discontinuation or dose adjustment is required. 1
*See How to prescribe Tivicay? for recommended dolutegravir dosing in patients with resistance to the integrase class.